Top

Pediatric Drugs

Published in:

Open Access 01-04-2013 | Review Article

Proton Pump Inhibitors in Pediatrics

Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics

Authors: Robert M. Ward, Gregory L. Kearns

Published in: Pediatric Drugs | Issue 2/2013

Abstract

Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications for treatment of adults and children. Their effectiveness for treatment of peptic conditions in the pediatric population, including gastric ulcers, gastroesophageal reflux disease (GERD), and Helicobacter pylori infections has been established for children older than 1 year. Studies of the preverbal population of neonates and infants have identified doses that inhibit acid production, but the effectiveness of PPIs in the treatment of GERD has not been established except for the recent approval of esomeprazole treatment of erosive esophagitis in infants. Reasons that have been proposed for this are complex, ranging from GERD not occurring in this population to a lack of histologic identification of esophagitis related to GERD to questions about the validity of symptom scoring systems to identify esophagitis when it occurs in infants. The effectiveness of PPIs relates to their structures, which must undergo acidic activation within the parietal cell to allow the PPI to be ionized and form covalent disulfide bonds with cysteines of the H⁺–K⁺-adenosine triphosphatase (H⁺–K⁺-ATPase). Once the PPI binds to the proton pump, the pump is inactivated. Some PPIs, such as omeprazole and rabeprazole bind to cysteines that are exposed, and their binding can be reversed. After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h. Cytochrome P450 (CYP) 2C19 and to a lesser degree CYP3A4 clear the PPIs metabolically. These enzymes are immature at birth and reach adult levels of activity by 5–6 months after birth. This parallels studies of the maturation of CYP2C19 to adult levels by roughly the same age after birth. Specific single nucleotide polymorphisms of CYP2C19 reduce clearance proportionally and increase exposure and prolong proton pump inhibition. Prolonged treatment of pediatric patients with PPIs has not caused cancer or significant abnormalities.

Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45(4):421–7.PubMedCrossRef

Heitzmann D, Warth R. No potassium, no acid: K⁺ channels and gastric acid secretion. Physiology (Bethesda). 2007;22:335–41.CrossRef

Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44(5):441–66.PubMedCrossRef

Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5(1):25–40.PubMed

Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70(5):1–11.CrossRef

Shin JM, Munson K, Vagin O, et al. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 2009;457(3):609–22.PubMedCrossRef

Sachs G, Shin JM, Vagin O, et al. The gastric H, K ATPase as a drug target: past, present, and future. J Clin Gastroenterol. 2007;41(Suppl 2):S226–42.PubMedCrossRef

Schubert ML. Gastric exocrine and endocrine secretion. Curr Opin Gastroenterol. 2009;25(6):529–36.PubMedCrossRef

Kaplan JH. Biochemistry of Na, K-ATPase. Annu Rev Biochem. 2002;71:511–35.PubMedCrossRef

10.

Sachs G, Shin JM, Besancon M, et al. Topology and sites in the H, K-ATPase. Ann N Y Acad Sci. 1992;671:204–16.PubMedCrossRef

11.

Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438–46.PubMedCrossRef

12.

Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(Suppl 2):2–8.PubMedCrossRef

13.

Li Y, Zhang W, Guo D, et al. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta. 2008;391:60–7.PubMedCrossRef

14.

Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 2010;6:17–28.PubMedCrossRef

15.

Hagymasi K, Mullner K, Herszenyi L, et al. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12(6):873–88.PubMedCrossRef

16.

Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821–6.PubMedCrossRef

17.

Abelo A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28(8):966–72.PubMed

18.

Kim KA, Kim MJ, Park JY, et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2003;31(10):1227–34.PubMedCrossRef

19.

Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(8):963–78.PubMedCrossRef

20.

Omari T, Lundborg P, Sandstrom M, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr. 2009;155(2):222–8.PubMedCrossRef

21.

Zhang W, Kukulka M, Witt G, et al. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Paediatr Drugs. 2008;10(4):265–74.PubMedCrossRef

22.

Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010;66(6):555–61.PubMedCrossRef

23.

Faure C, Michaud L, Shaghaghi EK, et al. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr. 2001;33(2):144–8.PubMedCrossRef

24.

Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1–24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45(5):530–7.PubMedCrossRef

25.

Heyman MB, Zhang W, Huang B, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;44(1):35–40.PubMedCrossRef

26.

Tammara BK, Sullivan JE, Adcock KG, et al. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. Clin Pharmacokinet. 2011;50(8):541–50.PubMedCrossRef

27.

Kearns GL, Andersson T, James LP, et al. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol. 2003;43(8):840–8.PubMedCrossRef

28.

Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol. 2000;95(11):3101–6.PubMedCrossRef

29.

Li J, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. Clin Ther. 2006;28(3):419–27.PubMedCrossRef

30.

Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther. 2001;15(9):1397–402.PubMedCrossRef

31.

Kearns GL, Blumer J, Schexnayder S, et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol. 2008;48(11):1356–65.PubMedCrossRef

32.

Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol. 2011;51(6):876–87.PubMedCrossRef

33.

Zannikos PN, Doose DR, Leitz GJ, et al. Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2011;52(6):691–701.PubMedCrossRef

34.

James L, Walson P, Lomax K, et al. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin Ther. 2007;29(9):2082–92.PubMedCrossRef

35.

Knebel W, Tammara B, Udata C, et al. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. J Clin Pharmacol. 2011;51(3):333–45.PubMedCrossRef

36.

Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965–74.PubMedCrossRef

37.

Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos. 2010;38(6):894–7.PubMedCrossRef

38.

Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135–53.PubMedCrossRef

39.

Boyle JT. Acid secretion from birth to adulthood. J Pediatr Gastroenterol Nutr. 2003;37(Suppl 1):S12–6.PubMedCrossRef

40.

Raczkowski V. Amendment #1 for lansoprazole pediatric Written Request. US FDA Center for Drug Evaluation and Research; 2001. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm073483.pdf. Accessed 21 December 2011.

41.

Raczkowski V. Written Request for esomeprazole sodium. US FDA Center for Drug Evaluation and Research; 2001. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM150948.pdf. Accessed 21 December 2011.

42.

Raczkowski V. Written request for pantoprazole sodium. US FDA Center for Drug Evaluation and Research; 2001. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm121765.pdf. Accessed 21 December 2011.

43.

Raczkowski V. Written Request for lansoprazole. US FDA Center for Drug Evaluation and Research; 1999. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm073475.pdf. Accessed: 21 December 2011.

44.

Omari TI, Haslam RR, Lundborg P, et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44(1):41–4.PubMedCrossRef

45.

Kierkus J, Furmaga-Jablonska W, Sullivan JE, et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Dig Dis Sci. 2011;56(2):425–34.PubMedCrossRef

46.

Food and Drug Administration Amendments Act of 2007 (Public Law 110-85). 2007. http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110.pdf. Accessed 28 December 2011.

47.

Best Pharmaceuticals for Children Act, January 4, 2002 (Public Law No. 107-109). 2002. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049876.htm. Accessed 28 December 2011.

48.

Food and Drug Administration Modernization Act of 1997 (Public Law 105-115). 1997. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. Accessed: 28 December 2011.

49.

Slocum C, Arko M, Di Fiore J, et al. Apnea, bradycardia and desaturation in preterm infants before and after feeding. J Perinatol. 2009;29(3):209–12.PubMedCrossRef

50.

Poets CF. Gastroesophageal reflux: a critical review of its role in preterm infants. Pediatrics. 2004;113(2):e128–32.PubMedCrossRef

51.

Peter CS, Sprodowski N, Bohnhorst B, et al. Gastroesophageal reflux and apnea of prematurity: no temporal relationship. Pediatrics. 2002;109(1):8–11.PubMedCrossRef

52.

Kimball AL, Carlton DP. Gastroesophageal reflux medications in the treatment of apnea in premature infants. J Pediatr. 2001;138:355–60.PubMedCrossRef

53.

Beitz J. Protonix Written Request. US FDA Center for Drug Evaluation and Research; 2007. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm121776.pdf. Accessed 21 December 2011.

54.

Beitz J. Protonix Amended Written Request. US FDA Center for Drug Evaluation and Research; 2006. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm121774.pdf. Accessed 21 December 2011.

55.

Beitz J. Lansoprazole Written Request-Amendment #4. US FDA Center for Drug Evaluation and Research; 2005. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm073521.pdf. Accessed 21 December 2011.

56.

Beitz J. Esomeprazole Written Request Amendment #3. US FDA Center for Drug Evaluation and Research; 2005. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM150950.pdf. Accessed 21 December 2011.

57.

Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154(4):514–20 e4.

58.

Gallo-Torres H. Briefing Document for June 11, 2002 Advisory Committee Meeting on the Proton-Pump Inhibitor (PPI) Template. Justification for Studies in Pediatric Patients. US FDA Center for Drug Evaluation and Research; 2002. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3870B1_02_Briefing%20document.pdf. Accessed 21 December 2011.

59.

Orenstein SR, Hassall E. Pantoprazole for symptoms of infant GERD: the emperor has no clothes! J Pediatr Gastroenterol Nutr. 2010;51(4):537 (author reply 537–9).

60.

Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1–11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2010;50(6):609–18.PubMedCrossRef

61.

Zimmermann AE, Walters JK, Katona BG, et al. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther. 2001; 23(5):660–79 (discussion 645).

62.

Marchetti F, Gerarduzzi T, Ventura A. Proton pump inhibitors in children: a review. Dig Liver Dis. 2003;35(10):738–46.PubMedCrossRef

63.

van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127(5):925–35.PubMedCrossRef

64.

Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr. 2003;37(Suppl 1):S52–9.PubMedCrossRef

65.

Higginbotham TW. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. Ann Pharmacother. 2010;44(3):572–6.PubMedCrossRef

66.

Monzani A, Oderda G. Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review. Clin Exper Gastro. 2010;3:17–25.

67.

Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008;53(2):385–93.PubMedCrossRef

Title: Proton Pump Inhibitors in Pediatrics
Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
Authors: Robert M. Ward
Gregory L. Kearns
Publication date: 01-04-2013
Publisher: Springer International Publishing AG
Published in: Pediatric Drugs / Issue 2/2013
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-013-0012-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Proton Pump Inhibitors in Pediatrics

Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

The Cost Effectiveness of Licensed Oromucosal Midazolam (Buccolam®) for the Treatment of Children Experiencing Acute Epileptic Seizures: An Approach When Trial Evidence is Limited

Pharmacokinetics of Antibacterial Agents in the CSF of Children and Adolescents

Bipolar Depression in Pediatric Populations

Management of Infantile Hemangiomas

Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis

Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date